Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IHL-675A

Small molecule · developed by Incannex Healthcare

Phase 2 Most advanced trial (none active)

IXHL Developer

1 Registered trials

What is IHL-675A?

IHL-675A is a combination product of cannabidiol (CBD) and hydroxychloroquine (HCQ) in a capsule, with the HCQ tablet contained within a CBD oil solution gel cap. It is studied in rheumatoid arthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Immunology
Developer: Incannex Healthcare Ltd (IXHL)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05942911	Phase 2	Rheumatoid Arthritis	Terminated	IXHL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rheumatoid Arthritis

More from Incannex Healthcare

IHL-42X Phase 2/3

Sources

ClinicalTrials.gov NCT05942911

Updated Oct 11, 2026. Something wrong or missing? Report it on the IXHL page.

Follow IXHL, the company behind IHL-675A

See IXHL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IXHL catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z